(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.29%) $83.81
(-1.10%) $1.620
(0.09%) $2 344.70
(0.43%) $27.47
(0.71%) $927.00
(-0.27%) $0.932
(-0.20%) $10.96
(-0.39%) $0.799
(-0.16%) $92.17
Live Chart Being Loaded With Signals
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs...
Stats | |
---|---|
Today's Volume | 52 727.00 |
Average Volume | 9 670.00 |
Market Cap | 525.30M |
EPS | $0 ( 2024-03-20 ) |
Next earnings date | ( $0.770 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.84 |
ATR14 | $0.0350 (0.46%) |
Valneva SE Correlation
10 Most Positive Correlations | |
---|---|
ALEC | 0.812 |
10 Most Negative Correlations | |
---|---|
BTBD | -0.801 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Valneva SE Financials
Annual | 2023 |
Revenue: | $153.71M |
Gross Profit: | $48.54M (31.58 %) |
EPS: | $-0.730 |
Q4 | 2023 |
Revenue: | $41.90M |
Gross Profit: | $15.83M (37.79 %) |
EPS: | $-0.230 |
Q3 | 2023 |
Revenue: | $38.07M |
Gross Profit: | $17.10M (44.91 %) |
EPS: | $-0.250 |
Q2 | 2023 |
Revenue: | $40.24M |
Gross Profit: | $6.88M (17.09 %) |
EPS: | $-0.120 |
Financial Reports:
No articles found.
Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators